Announcing the new book by DermNet NZ

Download a FREE sample chapter



Author: Weng Chyn Chan MB ChB, Dept of Dermatology Waikato Hospital, Hamilton, New Zealand, 2004.

Rifampicin is an antibiotic used to treat serious bacterial infections. It may be prescribed by dermatologists for the treatment of:

It is also used to treat brucellosis, serious staphylococcal infections and to clear asymptomatic carriers of Neisseria meningiditis (which can cause meningococcal disease).

Rifampicin is active against a variety of organisms including Staphylococcus aureus, Staphylococcus epidermidis, Mycobacterium tuberculosis, Mycobacterium leprae, Neisseria meningiditis and Brucella species.

It should always be prescribed with another antibiotic, in order to prevent bacterial resistance, which can develop rapidly if it is used alone.

It should be taken on an empty stomach at least 30 minutes before a meal or 2 hours after a meal. Antacids should be given at least 1 hour after rifampicin.

In New Zealand rifampicin is available as:

Side effects

Rifampicin is usually well tolerated and rarely causes serious toxicity. The commonest side effects involve skin and the gastrointestinal system.

Bodily fluids
Tears, sweat and urine may become orange coloured and contact lenses may be permanently stained.
Usually mild and self-limiting flushing and itching with or without rash. Hives are uncommon. Erythema multiforme and toxic epidermal necrolysis have rarely been reported.
Loss of appetite, vomiting, abdominal pain and diarrhoea.
Hepatitis, particularly if rifampicin is given with isoniazid
Thrombocytopenia (low platelets potentially resulting in bruising and bleeding), rarely low white blood cell count and disseminated intravascular coagulation, and very rarely agranulocytosis (severely decreased white blood cell counts).
Muscle weakness and myopathy are uncommon

Rifampicin is sometimes used intermittently (less than 2 to 3 doses per week) for the treatment of tuberculosis and leprosy. When rifampicin is used in this way, it may be associated with a ‘flu-like syndrome, shortness of breath, low blood pressure, acute renal failure and shock.

Drug interactions

Rifampicin is a P-glycoprotein inducer and may increase the breakdown of other medications, making them less effective. The dosage of these drugs may need adjustment if taken together with rifampicin:


Related information

Make a donation

Donate Today

Help us to update and maintain DermNet New Zealand

Submit your images

We are expanding our image library

Contact us

History of DermNet NZ

Watch Dr Amanda Oakley presenting 'The History Of DermNet NZ' at The International Society Of Teledermatology.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter